A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
Merus B.V.
Bicara Therapeutics
AstraZeneca
Endeavor Biomedicines, Inc.
EMD Serono
VM Oncology, LLC
EMD Serono
Inovio Pharmaceuticals
CDx Diagnostics
Novartis
Swedish Orphan Biovitrum
Eli Lilly and Company
Eli Lilly and Company
Sanofi
Siemens Molecular Imaging
Vical